Table 1 Clinical baseline characteristics in different response groups

n

20

9

11

Age (years), Mean ± SD

53.40 ± 10.67

53.89 ± 11.98

53.00 ± 10.05

0.859

Gender, n (%)

Female

11 (55.0)

6 (66.7)

3 (27.3)

0.175

Male

9 (45.0)

3 (33.3)

8 (72.7)

Diabetes, n (%)

3 (15.0)

2 (22.2)

1 (9.1)

0.566

Arterial hypertension, n (%)

3 (15.0)

2 (22.2)

1 (9.1)

0.566

Family history of cancer, n (%)

2 (10.0)

0 (0.0)

2 (18.2)

0.236

Body mass index (kg/m²⁾

23.68 ± 3.59

22.81 ± 1.43

24.39 ± 4.65

0.307

Smokers, n (%)

7 (35.0)

0 (0.0)

7 (63.6)

0.005

Anemia, n (%)

2 (10.0)

1 (11.1)

1 (9.1)

1.000

Tumor localization, n (%)

Inferior rectum (< 5 cm)

7 (35.0)

3 (33.3)

4 (36.4)

0.621

Mid rectum (5–10 cm)

12 (60.0)

6 (66.7)

6 (54.5)

Superior rectum (> 10 cm⁾

1 (5.0)

0 (0.0)

1 (9.1)

MRI

Tumor diameter (mm)

40.50 ± 13.66

43.00 ± 7.35

50.20 ± 16.88

0.247

Initial lateral lymph node dissemination, n (%)

10 (50.0)

5 (55.6)

5 (45.5)

1.000

cTNM, n (%)

II

6 (30.0)

2 (22.2)

4 (36.4)

0.850

III

10 (50.0)

5 (55.6)

5 (45.5)

Missing data

4 (20.0)

2 (22.2)

2 (18.2)

nCRT time (days), Median (Q1-Q3)

35 (33–35)

35 (34–39)

34 (32–35)

0.110

Surgery delay (days), Median (Q1-Q3)

55 (47–63)

60 (50–63)

48 (46–75)

0.381

Anus preservation, n (%)

11 (55.0)

6 (66.7)

5 (45.5)

0.406

R0 resection, n (%)

20 (100.0)

9 (100.0)

11 (100.0)

/